UncategorizedOxford Biohacking Society celebrates first-year anniversary Empower Meds / November 21, 2025
UncategorizedEpigenica enables ‘precise and scalable measurement’ of epigenetic changes Empower Meds / November 21, 2025
UncategorizedGero unveils AI model for small molecule design without structure Empower Meds / November 21, 2025
UncategorizedALS community petitions FDA to approve NurOwn stem cell therapy – Longevity.Technology Empower Meds / November 21, 2025
UncategorizedFDA accepts Denali Therapeutics’ BLA for tividenofusp alfa – Longevity.Technology Empower Meds / November 21, 2025
UncategorizedPulseSight launches first-in-human trial of AMD gene therapy Empower Meds / November 21, 2025
UncategorizedAI-driven aging model lands potential multibillion-dollar runway Empower Meds / November 21, 2025
UncategorizedBluerock Therapeutics begins trial of OpCT-001 for eye diseases – Longevity.Technology Empower Meds / November 21, 2025
UncategorizedHumacyte’s Symvess ECAT approved by U.S. Defense Logistics Agency – Longevity.Technology Empower Meds / November 21, 2025
UncategorizedRecursion acquires rights to REV102 for rare bone disorder – Longevity.Technology Empower Meds / November 21, 2025
